These results, as well as those of five-year disease-free survival (56.673 ± 0.871, 52.209 ± 2.113, 50.980 ± 2.357, and 42.897 ± 2.242 months, respectively, P < 0.001; Figure 6C), indicated that NGFR and S100A9 combined can improve the outcomes of CRC patients after 5-FU treatment. Here, NGFR is linked to colorectal carcinoma.